Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Pricing Debate

Set Alert for Pricing Debate

Rebate Reshuffle: Could Pharma Foot The Bill To Offset Higher Premiums?

Bernstein Research analysts said CMS could charge pharmaceutical manufactures a fee to offset increases in insurance premiums anticipated from the elimination of rebates in a "win-win" move.

Pricing Debate Reimbursement Medicare

Latest From Pricing Debate

The PBM Business Model, As Told To Sen. Cornyn

Execs offer (mostly) consistent responses as congressmen come out of the woodwork to grill the PBMs on their business practices.
Pharmacy Benefit Management Legislation

PBMs On Capitol Hill: Why Pharma Will Miss Them When They Are Gone

Drug pricing “middlemen” had their day in the hot seat during a Senate Finance Committee hearing on drug pricing. But even amid the finger-pointing between industry and PBMs over the high cost of drugs, the PBM execs offered some strong reminders of their real value to industry in fending off more overt price interventions by government.  
Pharmacy Benefit Management Pricing Debate

The Return Of The “Specialty” Drug Pricing Debate In The US

Pharma has been almost wholly successful in shifting the ground in the US drug pricing debate away from high-cost “specialty” products and towards the large gap between list and net prices, with the most intense focus on older medicines like insulin. What happens when the debate shifts back?
Pricing Debate Reimbursement

Annuity Payments For Costly One-Off Drugs Is No Magic Bullet

Paying for expensive one-off treatments in installments rather than one lump sum could be appropriate for some products, but fails to address wider systemic problems.

Gene Therapy Market Access

Insulin Prices: House Hearing Displays Bipartisan Commitment To Rapid Reform

Reform "is going to happen,” promised Energy & Commerce Oversight Subcommittee Chair Diana DeGette, suggesting the panel’s next hearing on insulin price reform may be held in July.

Pricing Debate Legislation

Insulin Assistance Programs: Big Help Or Just A Band-Aid?

Drug makers and other stakeholders have been rolling out insulin savings programs as the high cost of insulins come under scrutiny on Capitol Hill. Sanofi announced an expanded cost-savings program during a House hearing, but one Congresswoman called them a band-aid. 

Pricing Debate Policy & Regulation

Blow For Novartis As England’s NICE Says No To Kisqali

Novartis is having a harder time than Eli Lilly at getting health technology assessment body NICE to agree to make its breast cancer CDK4/6 inhibitor in combination with fulvestrant available on the National Health Service.

Health Technology Assessment Pricing Debate

PBMs Were On Capitol Hill, But Pharma Still Took Some Heat

Drug makers remained front and center during the Senate Finance Committee's third hearing on drug pricing, even though leaders from five pharmacy benefit managers were testifying.

Pricing Debate Politics

Senate Panel Questions Early PBM Response To Repatha Price Cut

Rebate expectations appear to have got in the way of fast uptake for some of the leading pharmacy benefit managers, according to comments by executives at the Senate Finance Committee hearing April 9.

Reimbursement Pricing Debate
See All